Portfoliotracker

Scancell Holdings plc

SCLP.L · LSE · Healthcare Biotechnology 0/100 E

80,45 GBP
▼ −3,55 (−4,22 %)
Trading delayed by 15 min
Price as of 17. 11. 13:09, fetched 17. 11. 13:40
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap81,5 mld. GBP P/E– Forward P/E-362,1 P/S17 301,4 P/B– EV/EBITDA– Dividend yield– FCF yield-0,01 % EPS-0,17 GBP Net margin0,0 % Return on equity– Beta0,74 Debt / equity–
52-week range 79,00 to 295,00
3-month average volume0,2 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. The company's product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCIB1+ that is in Phase III for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase III clinical trials for the treatment of solid tumors, including renal cell carcinoma, head, and neck; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company offers GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which promotes receptor clustering thereby improving immune signaling. Further, it provides pre-clinical products, such as SC129 and SC2811 for solid tumors; SC27; and GT 200 for ovarian cancer. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Employees
55
Country
United Kingdom
Data since
12. 2. 2010

Explore further

Similar companies AVCT.L

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account